Back to top
more

BioDelivery Sciences International, Inc. (BDSI)

(Delayed Data from NSDQ)

$4.84 USD

4.84
695,323

+0.08 (1.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.85 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Mylan (MYL) Q2 Earnings: Is a Disappointment in the Cards?

Investors will focus on the performance of EpiPen, newly launched biosimilars along with other updates from Mylan's (MYL) pipeline, when it reports Q2 results (scheduled for Aug 8).

    Prothena (PRTA) Q2 Earnings: Is a Disappointment in Store?

    Prothena's (PRTA) Q2 results are likely to reflect pipeline updates along with progress with its restructuring plan.

      Envision Healthcare (EVHC) Q2 Earnings: What's in Store?

      Envision Healthcare (EVHC) Q2 earnings should gain from higher revenues from thePhysician Service segment and gains from cost control initiatives.

        Is a Beat in the Cards for Nektar (NKTR) in Q2 Earnings?

        Nektar Therapeutics (NKTR) is likely to beat estimates when it reports second-quarter results. Investors are expected to focus on pipeline progress.

          Is a Beat in Store for Radius Health (RDUS) in Q2 Earnings?

          Investors will focus on lead drug Tymlos' uptake and an update on Radius Health's (RDUS) marketing application for the drug in Europe, when it reports second-quarter results on Aug 7.

            What Lies in Store for Ligand (LGND) This Earnings Season?

            Ligand's (LGND) Captisol formulation technology is expected to drive milestone and royalty payments in second-quarter 2018.

              What's in the Cards for Conatus (CNAT) This Earnings Season?

              On Conatus' (CNAT) second-quarter 2018 conference call, investor focus will remain on the company's progress with respect to its lead candidate, emricasan.

                What's in the Cards for Agios (AGIO) Stock in Q2 Earnings?

                On Agios' (AGIO) second-quarter 2018 conference call, investor focus is likely to be on the launch preparations of the company's newly FDA approved leukemia drug, Tibsovo.

                  Teva (TEVA) Q2 Earnings Coming Up: What's in the Cards?

                  While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

                    BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?

                    BioMarin (BMRN) is likely to see continued momentum in Kuvan and Vimizim sales in the second quarter. On the call, management is likely to comment on the launch preparation for pegvaliase.

                      What's in Store for Celldex (CLDX) This Earnings Season?

                      With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus is expected to be on the company's immuno-oncology pipeline in second-quarter earnings.

                        What's in the Cards for Arena (ARNA) This Earnings Season?

                        With no marketed product, investors will likely focus on Arena's (ARNA) efforts to develop its pipeline on second-quarter earnings call.

                          Is a Beat in Store for Vertex (VRTX) This Earnings Season?

                          Vertex Pharma (VRTX) is expected to beat estimates when it reports second-quarter earnings on Jul 25.

                            BioDelivery (BDSI) Q1 Earnings and Sales Beat Estimates

                            BioDelivery Sciences' (BDSI) reports narrower-than-expected loss in Q1. Sales marginally beat the consensus mark.

                              Ekta Bagri headshot

                              Xiaflex & Sterile Injectables Drive Endo's (ENDP) Q1 Earnings

                              Endo's (ENDP) first-quarter results beat earnings on both counts driven by growth in Xiaflex and sterile injectables.

                                What's in Store for Endocyte (ECYT) This Earnings Season?

                                Endocyte (ECYT) is expected to provide updates on pipeline candidates when it reports first-quarter 2018 results on May 9 after the market closes.

                                  5 Biotech Stocks Set to Beat Estimates This Earnings Season

                                  Given the large number of biotech firms, the task of selecting stocks with possibilities to beat estimates could appear daunting. We pick five biotech stocks likely to deliver an earnings surprise.

                                    BioDelivery Sciences (BDSI) Q1 Earnings: What to Expect?

                                    Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).

                                      Why Is BioDelivery Sciences (BDSI) Up 2.4% Since Its Last Earnings Report?

                                      BioDelivery Sciences (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        BioDelivery Sciences (BDSI) in Focus: Stock Moves 5.1% Higher

                                        Shares of BioDelivery Sciences (BDSI) rose over 5% yesterday.

                                          BioDelivery (BDSI) Q4 Loss Wider-Than-Expected, Sales Up Y/Y

                                          BioDelivery (BDSI) reports wider-than-expected loss in Q4. However, revenues surpass estimates and increase substantially year over year.

                                            What's in the Cards for Inovio (INO) This Earnings Season?

                                            Inovio's (INO) most advanced pipeline candidate, VGX-3100's consistent progress might drive the stock in Q4. However, lack of an approved product in the company's portfolio is a dampener.

                                              What's in the Cards for Arena (ARNA) This Earnings Season?

                                              Although Arena's (ARNA) only approved product, Belviq, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q4.

                                                What's in the Cards for BioDelivery (BDSI) in Q4 Earnings?

                                                BioDelivery's (BDSI) lead drugs Belbuca and Bunavail look promising to deliver an earnings beat in Q4.

                                                  Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4

                                                  Endo International (ENDP)'s fourth quarter results surpassed expectations but were down year-over-year due to weakness in the generics business.